Home/Pipeline/Undisclosed (Liver)

Undisclosed (Liver)

Wilson Disease

PreclinicalActive

Key Facts

Indication
Wilson Disease
Phase
Preclinical
Status
Active
Company

About Prime Medicine

Prime Medicine's mission is to deliver on the promise of Prime Editing, a next-generation gene editing technology designed to correct the vast majority of disease-causing mutations with high precision and safety. The company has advanced from foundational research into the clinic, with initial programs for chronic granulomatous disease (CGD) and other indications now generating early human data. Its strategy leverages a single, versatile platform to build a broad pipeline of one-time therapies, aiming to transform treatment paradigms across genetic medicine.

View full company profile

Other Wilson Disease Drugs

DrugCompanyPhase
Copper ChelatorDepYmedPre-clinical
Trientine Tetrahydrochloride (Cuprior®/Cuvrior®)OrphalanApproved
UX701Ultragenyx PharmaceuticalPhase 1/2
ALXN1840Monopar TherapeuticsPhase 3